Cost analysis of glaucoma medications: A 3-year review

Journal of Glaucoma

Volumn 11, Issue 4, 2002, Pages 354-358

  Vold, Steven D ^a   Riggs, William L ^a   Jackimiec, John ^a  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGLAUCOMA AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BRIMONIDINE; BRINZOLAMIDE; CARTEOLOL; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; LATANOPROST; LEVOBUNOLOL; METIPRANOLOL; TIMOLOL; TIMOLOL MALEATE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; EYE DISEASE; GLAUCOMA; HEALTH ECONOMICS; HUMAN; INTRAOCULAR HYPERTENSION; PRIORITY JOURNAL;

EID: 0036331617     PISSN: 10570829     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9394(03)00036-9     Document Type: Article

References (16)

1. Position paper. Making medicines affordable: The price factor
2. Some HMOs now put doctors on a budget for prescription drugs
3. Exhaustion of drug benefits and disenrollment of Medicare beneficiaries from managed care organizations
4. Compliance in patients prescribed eyedrops for glaucoma
5. Cost analysis of glaucoma medications
6. Quantitative and cost evaluation of three antiglaucoma beta-blocker agents: Timoptic-XE versus two generic levobunolol products
7. Comparison of timolol maleate and levobunolol: Doses and volume per bottle
8. Drop size of commercial glaucoma medications
9. Daily cost of beta-adrenergic blocker therapy
10. Cost of beta-adrenergic receptor blocking agents for ocular hypertension
11. Daily cost of newer glaucoma agents
12. Cost considerations of medical therapy for glaucoma